首页 | 本学科首页   官方微博 | 高级检索  
检索        


Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI)
Authors:Gabor G Toth  Bernard De Bruyne  Petr Kala  Flavio L Ribichini  Filip Casselman  Ruben Ramos  Zsolt Piroth  Stephane Fournier  Carlos Van Mieghem  Martin Penicka  Martin Mates  Frank Van Praet  Ivan Degriek  Emanuele Barbato
Institution:1.Department of Cardiology, University Heart Center Graz,Medical University of Graz,Graz,Austria;2.Cardiovascular Research Center Aalst, OLV Clinic,OLV Hospital,Aalst,Belgium;3.Department of Cardiology and Internal Medicine,University Hospital Brno and Medical Faculty of Masaryk University,Brno,Czech Republic;4.Division of Cardiology, Department of Medicine,University of Verona,Verona,Italy;5.Hospital Santa Marta - Centro Hospitalar Lisboa Central,Lisbon,Portugal;6.Hungarian Institute of Cardiology,Budapest,Hungary;7.Cardiovascular Center,Na Homolce Hospital,Prague,Czech Republic;8.Division of Cardiology, Department of Advanced Biomedical Sciences,Federico II University,Naples,Italy
Abstract:Clinical benefit of invasive functionally guided revascularization has been mostly investigated and proven for percutaneous coronary intervention. It has never been prospectively evaluated whether a systematic fractional flow reserve (FFR) assessment is also beneficial in guiding coronary artery bypass graft surgery (CABG). The objective of the GRAft patency after FFR-guided versus angiography-guIded CABG (GRAFFITI) trial was to compare an FFR-guided revascularization strategy to the traditional angiography-guided revascularization strategy for patients undergoing CABG. Patients were enrolled with significantly diseased left anterior descending or left main stem and at least one major coronary artery with angiographically intermediate stenosis (30–90% diameter stenosis) that was assessed by FFR. Thereafter, while the FFR values were kept concealed, cardiac surgeons decided their intended procedural strategy based on the coronary angiography alone. At this point, patients underwent 1:1 randomization to either an FFR-guided or an angiography-guided CABG strategy. In case the patient was randomized to angiography-guided arm, cardiac surgeons kept their intended procedural strategy, i.e., CABG was guided solely on the basis of the coronary angiography. In case the patient was randomized to the FFR-guided arm, FFR values were disclosed to the surgeons who revised the surgical protocol according to the functional significance of each coronary stenosis. The primary endpoint of the trial was the rate of graft occlusion at 12 months, assessed by coronary computed tomography or coronary angiography. The secondary endpoints were (1) length of postoperative hospital stay; (2) changes in surgical strategy depending upon FFR results (in FFR-guided group only); and (3) rate of major adverse cardiac and cerebrovascular events, i.e., composite of death, myocardial infarction, stroke, and any revascularization during the follow-up period. This study is the first prospective randomized trial investigating potential clinical benefits, associated with FFR-guided surgical revascularization. Trial registration: NCT01810224
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号